A recent study revealed that corticotropin-releasing hormone (CRH) in the cerebral cortex (CTX) plays a regulatory role in emotional behaviors in rodents. Given the functional interaction between brain-derived neurotrophic factor (BDNF) and the CRH-signaling pathway in the hypothalamic-pituitary-adrenal axis, we hypothesized that BDNF may regulate gene expression of CRH and its related molecules in the CTX. Findings of real-time quantitative PCR (RT-qPCR) indicated that stimulation of cultured rat cortical neurons with BDNF led to marked elevations in the mRNA levels of CRH and CRH-binding protein (CRH-BP). The BDNF-induced up-regulation of CRH-BP mRNA was attenuated by inhibitors of tropomyosin related kinase (Trk) and MEK, but not by an inhibitor for PI3K and Phospholipase C gamma (PLCc). The up-regulation was partially blocked by an inhibitor of lysine-specific demethylase (KDM) 6B. Fluorescent imaging identified the vesicular pattern of pH-sensitive green fluorescent protein-fused CRH-BP (CRH-BP-pHluorin), which co-localized with mCherry-tagged BDNF in cortical neurons. In addition, live-cell imaging detected drastic increases of pHluorin fluorescence in neurites upon membrane depolarization. Finally, we confirmed that tetrodotoxin partially attenuated the BDNF-induced up-regulation of CRH-BP mRNA, but not that of the protein. These observations indicate the following: In cortical neurons, BDNF led to gene expression of CRH-BP and CRH. TrkB, MEK, presumably ERK, and KDM6B are involved in the BDNF-induced gene expression of CRH-BP, and BDNF is able to induce the up-
regulation in a neuronal activity-independent manner. It is suggested that CRH-BP is stored into BDNF-containing secretory granules in cortical neurons, and is secreted in response to membrane depolarization.
Keywords: BDNF, CRH-BP, CRH, cerebral cortical neurons, TrkB. J. Neurochem. (2018) 146, 99--110. Corticotropin-releasing hormone (CRH), also known as corticotropin-releasing factors, signals through two distinct G-protein coupled receptors, namely the CRH receptor type I and II (CRHR1 and 2) (Westphal and Seasholtz 2006) . The bioavailability of CRH is thought to be regulated by CRHbinding protein (CRH-BP) via its binding to CRH (Westphal and Seasholtz 2006) . In the hypothalamus, CRH is secreted from hypophysiotropic paraventricular nucleus neurons, leading to the secretion of proopiomelanocortin and subsequent production of its derivatives, including adrenocorticotrophin and alpha-melanocyte-stimulating hormone (a-MSH), in the pituitary gland (Cawley et al. 2016) . Subsequently, adrenocorticotrophin induces the release of the glucocorticoid stress hormone, which is the primary negative regulator of the hypothalamic-pituitary-adrenal (HPA) axis activity, from the adrenal glands (Westphal and Seasholtz 2006) . CRH-BP, CRH, and CRHRs are also expressed in the cerebral cortex (CTX) (Petrusz et al. 1985; Millan et al. 1986) . Recently, Li et al. demonstrated that oxytocin receptor interneurons (OxtrINs) in the medial prefrontal cortex coordinate sexually dimorphic social/emotional behaviors via the regulation of CRH bioactivity by CRH-BP. In particular, in the mouse medial prefrontal cortex, oxytocin receptor interneurons specifically express CRH-BP and, in male animals, it blocks CRH-induced activation of pyramidal neurons, which regulate emotional behaviors . The brain-derived neurotrophic factor (BDNF) is a member of a family of neurotrophins that plays a pivotal role in neuronal differentiation, structure, and function (Hempstead 2015) . BDNF functionally interacts with the HPA axis via the regulation of the CRH-signaling pathway. In particular, ectopic expression of BDNF in vivo led to increases in CRH protein levels, and reduced the expression of BDNF. Furthermore, its receptor tropomyosin related kinase B (TrkB) decreased the CRH levels, which then induced impairments in the HPA function (Jeanneteau et al. 2012) . Although the CRHR1 mRNA levels were reported to be up-regulated 4 h after the BDNF treatment in cultured neurons from the frontal cortex of rat (Jørgensen et al. 2013) , it remains largely unknown whether BDNF regulates the gene expression of CRH and its related molecules, other than CRHR1.
In paraventricular neurons, CRH is localized in the densecore secretory granules (Kiss and Bertini 1992) , which are exocytic organelles that are responsible for the regulated secretion of cargo molecules upon stimulation (Malosio et al. 2004) . Blanco et al. (2011) reported the localization of CRH-BP in secretogranin II (SecII)-positive vesicles in a rat adrenal pheochromocytoma cell line (PC12 cells), and showed that it was secreted upon high-potassium (K) stimulation, indicating that CRH-BP is stored in the regulatory secretory pathway and secreted in an activity-dependent manner in those cells. A recent study has demonstrated that CRH-BP in PC12 cells induced the insertion of CRHR2 into the cell surface via its binding to CRHR2 (Slater et al. 2016) . However, the subcellular localization or secretory fashion of CRH-BP in central nervous system (CNS) neurons has not been fully assessed.
The objectives of this study were (i) to evaluate whether and how BDNF regulates the expression of CRH-BP and its related molecules, CRH and CRHRs, in cortical neurons, and (ii) to determine how CRH-BP is secreted from cortical neurons.
Materials and methods

Materials
The pH-sensitive green fluorescent protein-fused CRH-BP (CRH-BP-pHluorin) was constructed from the CRH-BP gene (NM_139183) with pHluorin in the pcDNA3.1 vector. Recombinant BDNF was kindly provided by Sumitomo Pharmaceuticals (Osaka, Japan). The same BDNF-mCherry construct that was generated in our previous study (Adachi et al. 2015) was used here. Wistar rats (strain Slc:W; RRID:RGD_2314928) were from NIPPON SLC (Hamamatsu, Japan). All efforts were made to minimize animal suffering and the number of animals used for the studies: Animals were housed, handled, and bred according to Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions by Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. All animal experiments (see "Cell cultures and gene transfections" section for details) were conducted in strict accordance with the protocols approved by the Institutional Animal Care and Use Committee of Kagawa University, Kwansei Gakuin University, and University of Occupational and Environmental Health. The study was not preregistered.
Cell cultures and gene transfections
Primary cultures of dissociated cerebral cortical neurons were prepared from rats (Wistar, both sexes) at embryonic day 20 (E20). The animals were exposed to isoflurane in air until they became unconscious. The adequacy of anesthesia was confirmed by disappearance of eyelid reflex, corneal reflex, and loss of muscular tone. The animals were then immediately killed by cervical dislocation, followed by decapitation, ensuring minimal suffering of the animals. The neurons were cultured in serum-free neurobasal medium (Gibco, Rockville, MD, USA) containing B27 supplement (Gibco) at a final density of 2 9 10 6 cells on six-well plates coated with polyethyleneimine for the real-time quantitative polymerase chain reaction (RT-qPCR) assay. Cultures were incubated with medium containing 1 lM cytosine arabinoside to suppress glial growth after 3 days in vitro (DIV3). BDNF was applied from DIV6 or DIV7 for 3 days. Gene transfection was carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in OptiMinimal Essential Medium medium (Invitrogen), according to the manufacturer's instructions. Imaging or cell fixation were carried out 24 h after gene transduction.
Quantification of mRNA levels
Real-time quantitative PCR (RT-qPCR) was carried out as described previously (Suzuki et al. 2017) . Briefly, total RNA was purified from neurons using an RNeasy mini kit (QIAGEN, Valencia, CA, USA) and amplified using the ABI Step One Plus RT-PCR (Applied Biosystems, Foster City, CA, USA) and One
Step SYBR PrimScript RT-PCR Kit II (Takara Bio, Otsu, Japan) with the following primer sets: Crhbp (forward, 5ʹ-TGGACTGGACACCTCCAAGAT-3ʹ; reverse, CRH-BPr; 5ʹ-ACTCCGGGATGCTGTTTCTG-3ʹ) (De Luca et al. 2014) ; Crh (forward, 5ʹ-AACTCAGAGCCCAAGTA CGTTGAG-3ʹ; reverse, 5ʹ-TCACCCATGCGGATCAGAATC-3ʹ) (Lee et al. 2013) , Crhr1 (forward, 5ʹ-GGTGACAGCCGCCTAC AATT-3ʹ; reverse, 5ʹ-AAGGTACACCCCAGCCAATG-3ʹ) (De Luca et al. 2014) ; Crhr2 (forward, 5ʹ-TGGTGCATACCCTGCCCT AT-3ʹ; reverse, 5ʹ-GTGGAGGCTCGCAGTTTTGT-3ʹ) (De Luca et al. 2014) ; Kdm6a (forward, 5ʹ-GCAAACTGGAGAGACACCT AAC-3ʹ; reverse, 5ʹ-CATGGCTAGGACTGCAAACA-3ʹ); and Kdm6b (forward, 5ʹ-CCTTTGCATCTCTACGGTCTTC-3ʹ; reverse, 5ʹ-GT GGCTTCTTCTCCTCTTCTTG-3ʹ). Glyceraldehyde-3-phosphate dehydrogenase was also amplified using a primer set (forward, 5ʹ-T GCACCACCAACTGCTTAG-3ʹ; reverse, 5ʹ-GGATGCAGGGAT GATGTTC-3ʹ) (Suzuki et al. 2007) , and was used as a housekeeping gene. Analyses of PCR amplifications were performed using Step One Plus RT-PCR (Applied Biosystems). To confirm the amplification specificity, we subjected PCR products to dissociation curve analysis and gel electrophoresis on a 2% agarose gel to ensure the melting temperature and size of the DNA fragment. Expression levels for each mRNA were estimated by normalization to Glyceraldehyde-3-phosphate dehydrogenase levels measured in the same samples. 
Immunoblot
Immunocytochemistry
Immunocytochemistry was performed as previously described (Adachi et al. 2015) . In short, cultured cortical neurons were fixed with Dulbecco's phosphate-buffered saline-based 4% paraformaldehyde solution containing 4% sucrose for 20 min at 20 to 25°C. The cells were treated with 0.2% Triton-X/phosphate-buffered saline for 5 min and blocked by 10% goat serum in phosphate-buffered saline for 1 h at 37°C. Cells were subsequently incubated with antilysosome-associated membrane protein 2 (LAMP2) antibody (1 : 500; Thermo Fisher Scientific, Waltham, MA, USA; Cat# PA1-655, RRID: AB_2134625) overnight at 4°C. The secondary antibody used in this study was Alexa Fluor 546 (1 : 1000; Molecular Probes, Eugene, OR; Cat# A-11035, RRID: AB_143051). Fluorescent images were obtained using a Leica TCS SP8 system (Leica Solms, Germany).
Live-cell imaging
Live-cell imaging was carried out as previously described (Adachi et al. 2015) . Images of cortical neurons expressing fluorescent proteintagged CRH-BP were captured using an Axio Observer Z1 fluorescence microscope equipped with a Plan-AGSK-J4hromat 40 9 /1.3 oil immersion objective lens and a Colibri LED light source (Carl Zeiss). Time-lapse recordings were performed 18-24 h after transfection of CRH-BP-pHluorin. During the time-lapse imaging, the cultured neurons were perfused with a buffer containing 120 mM NaCl, 1.2 KH 2 PO 4 , 2 mM CaCl 2 , 1 mM MgSO 4 , 30 mM glucose, and 20 mM N-2-hydroxyethylpiperazine-Nʹ-2-ethanesulfonic acid (HEPES; pH 7.4), and incubated at 37°C. Sequential images were acquired using a cooled CCD camera (Carl Zeiss) with approximately 1-s interval and 200-600 ms exposure time. The secretion of CRH-BP-containing granules was analyzed by measuring the intensities of the fluorescent signal of pHluorin tagged with CRH-BP in dendrites as a function of time using the Axiovision software (Carl Zeiss).
Statistical analyses
Significance was analyzed using one-way or two-way ANOVA. Post hoc comparison of means was carried out with Tukey's test for multiple comparisons, when appropriate. A p value of 0.05 or less was considered statistically significant. The data were expressed as the means AE standard error of the mean (SEM). All experiments were performed at least twice to confirm reproducibility. Authors were not blinded to the results and no randomization was performed. Representative results from single experiments are presented in the figures.
Results
BDNF-induced up-regulation of CRH-BP, CRH, and CRHR1 in cortical cultures
We first evaluated the impact of BDNF on gene expression of CRH and its related molecules, CRHRs and CRH-BP, in cortical neurons. Primary cerebral cortical cultures were prepared from E20 rats. In this cerebral culture system, we have previously reported over 90% MAP-2-positive neurons, while glial fibrillary acidic protein-positive astrocytes and oligodendrocyte marker O4-positive oligodendrocytes accounted for only 5.4% and 0.2%, respectively (Suzuki et al. 2007) . We have also previously demonstrated that BDNF (100 and 10 ng/mL) led to the phosphorylation of TrkB in this culture system (Suzuki et al. 2017) . The cultures were treated with 100 ng/mL BDNF for 3 days (DIV6-9), and gene expression levels were measured by RT-qPCR (Fig. 1a) . The results indicated that BDNF significantly enhanced the gene expression of CRH (BDNF-treated: 4.98 AE 0.17, Control: 1.00 AE 0.02; p < 0.001). BDNF also induced slight, but significant, elevations in mRNA levels of CRHR1 (BDNF-treated: 1.36 AE 0.10, Control: 1.00 AE 0.06; p < 0.001), but not for CRHR2 (BDNF-treated: 1.09 AE 0.05, Control: 1.00 AE 0.05; p > 0.05). The results also indicated that BDNF strongly up-regulated the expression of CRH-BP (BDNF-treated: 6.99 AE 0.34, Control: 1.00 AE 0.02; p < 0.001). Stimulation of the culture with 10 ng/mL BDNF, which is expected to activate mainly the high-affinity BDNF receptor, TrkB, but not the low-affinity receptor, p75 NTR (Teng et al. 2005) , also induced a significant elevation of CRH-BP gene expression levels (BDNFtreated: 4.03 AE 0.28, Control: 1.00 AE 0.05; p < 0.001; Fig. 1b) , indicating a potential involvement of TrkB in the BDNF-induced up-regulation of CRH-BP mRNA. We also assessed the time course of the BDNF-induced up-regulation of CRH-BP mRNA. The cultures were treated with 100 ng/ mL BDNF for 1, 2, and 3 days, and gene expression levels were measured by RT-qPCR (Fig. 1c) . BDNF significantly enhanced the gene expression of CRH-BP 1 day (BDNFtreated: 26.40 AE 1.10, Control: 1.00 AE 0.03; p < 0.001), 2 days (BDNF-treated: 19.23 AE 0.26, Control: 0.97 AE 0.10; p < 0.001), and 3 days (BDNF-treated: 20.88 AE 0.90, Control: 1.09 AE 0.08; p < 0.001) after the treatment. Subsequently, the cultures were stimulated with or without BDNF (10 or 100 ng/mL), and the protein levels of CRH-BP were assessed 3 days after the BDNF treatment by western blot analysis (Fig. 1d) . The CRH-BP protein level was also significantly up-regulated in a BDNF-dose-dependent manner (100 ng/mL BDNF: 1.97 AE 0.04, p < 0.05 compared to 0 ng/mL BDNF: 1.00 AE 0.09; 10 ng/mL BDNF: 1.47 AE 0.07, p < 0.05 compared to 0 ng/mL BDNF). These findings indicated that in cerebral cortical cultures, BDNF markedly up-regulated CRH mRNA and CRH-BP mRNA and protein, and significantly but slightly CRHR1 mRNA. It was suggested that TrkB is involved in the BDNF-induced up-regulation of CRH-BP mRNA.
BDNF up-regulated CRH-BP mRNA and protein in a TrkBdependent manner in cortical cultures We assessed whether TrkB is involved in BDNF-induced upregulation of CRH-BP mRNA in cerebral cortical cultures, using K252a, a Trk receptor inhibitor. Cortical cultures were treated with 100 ng/mL BDNF in the presence or absence of 200 nM K252a for 3 days. In our previous study, we confirmed that K252a inhibits the BDNF-induced phosphorylation of TrkB under the identical conditions to the ones used here (Suzuki et al. 2004) . The BDNF-induced CRH-BP mRNA up-regulation (BDNF-treated: 6.74 AE 0.23, Control: 1.00 AE 0.06; p < 0.001) was significantly inhibited by K252a (BDNF-treated: 2.00 AE 0.42, Control: 2.05 AE 0.12; p > 0.05; two-way ANOVA interaction effect, F 1,8 = 135.62; p < 0.001; Fig. 2a ). CRH-BP protein levels were evaluated by western blot analysis (Fig. 2b) . BDNF-induced CRH-BP up-regulation (BDNF-treated: 1.80 AE 0.02, Control: 1.00 AE 0.04; p < 0.05) was blocked in the presence of K252a (BDNF-and K252a-treated: 0.96 AE 0.04, p > 0.05 compared to K252a-treated: 0.93 AE 0.01; p < 0.05 compared to BDNF-treated; Fig. 2b ). These observations indicated that BDNF induced CRH-BP gene expression in cerebral cortical neurons in a TrkB-dependent manner.
Involvement of MEK in the BDNF-induced up-regulation of CRH-BP mRNA in cortical cultures Subsequently, we sought for TrkB's downstream signaling molecules that are involved in the BDNF-induced upregulation of CRH-BP. Cortical cultures were treated over 3 days with 100 ng/mL BDNF in the presence or absence of LY293002 (10 lM), an inhibitor of Phosphoinositide 3-kinase (PI3K), or U0126 (10 lM), an inhibitor of mitogenactivated protein kinase/Extracellular signal-regulated kinase kinase (MEK), and the amount of CRH-BP mRNA was measured (Fig. 3) . The BDNF-induced CRH-BP up-regulation (BDNF-treated: 21.7 AE 0.79, Control: 1.00 AE 0.03; p < 0.001) was slightly, but significantly, enhanced in the presence of LY293002 (BDNF-and LY293002-treated: 26.1 AE 1.55, LY293002-treated: 0.86 AE 0.02; p < 0.001). On the other hand, the BDNF-induced CRH-BP upregulation was partially, but significantly, inhibited by U0126 (BDNF-and U0126-treated: 14.6 AE 0.69, U0126-treated: 0.44 AE 0.04; p < 0.001; Fig. 3a ). There was a significant interaction effect between BDNF stimulation and inhibitor application (two-way ANOVA, F 1,12 = 26.61, p < 0.001). These findings indicated that MEK and PI3K regulate the BDNF-induced gene expression of CRH-BP, positively and negatively, respectively. We assessed whether U0126 and LY293002 attenuated the BDNF-induced activation of downstream molecules for MEK and PI3K in our culture system. The cultures were pre-treated with or without the inhibitors for 20 min, and western blot analysis was carried out 5 min after the BDNF treatment (Fig. S1 ). In the presence of 10 lM U0126, phosphorylation of extracellular signal-regulated kinase (ERK; a downstream molecule for MEK), was markedly blocked, and no changes in amount of ERK protein were observed. Phosphorylation levels of Akt, a downstream molecule for PI3K, were decreased in the presence of 10 lM LY293002, while there were no changes in amount of Akt protein. These observations indicate that U0126 and LY293002 distinctively attenuated the activation of downstream signaling pathways for their target molecules, MEK and PI3K, respectively. Additionally, we observed that U73122, an inhibitor for Phospholipase C gamma PLCc (BDNF-and U73122-treated: 26.6 AE 5.80, U73122-treated: 0.75 AE 0.05; p < 0.01) failed to inhibit (two-way ANOVA, interaction effect: F 1,12 = 0.043, p > 0.05) the BDNFinduced up-regulation of CRH-BP mRNA (BDNF-treated: 24.8 AE 7.82, Control: 1.00 AE 0.07; p < 0.05; Fig. 3b ). This suggests that PLCc is not involved in the BDNF-induced gene expression of CRH-BP in cortical neurons.
Epigenetic regulations of the BDNF up-regulated CRH-BP gene expression in cortical cultures
Since the BDNF-induced up-regulation of CRH-BP was detected 3 days after the stimulation, it is plausible that epigenetic regulation may take part in this up-regulation. We assessed whether any epigenetic regulation was involved in Fig. 1 Brain-derived neurotrophic factor (BDNF) treatment enhanced gene expressions of corticotropin-releasing hormone-binding protein (CRH-BP) and its related genes, CRH and CRH receptor 1 (CRHR1) in rat cerebral cortical neuronal cultures. (a) Primary cultures of rat cerebral cortical neurons were treated with or without BDNF (100 ng/mL) for 3 days and expression levels of CRH-BP, CRH, CRHR1, and CRHR2 mRNA were measured by real-time quantitative polymerase chain reaction (RT-qPCR). N.S.: not significant, *p < 0.05, ***p < 0.001, Student's t-test, n = 6 independent culture dishes. (b)
The amount of CRH-BP mRNA 3 days after the treatment with 10 ng/mL of BDNF in primary cerebral cortical cultures. ***p < 0.001, Student's t-test, n = 3 independent culture dishes. (c) The cortical cultures were treated with BDNF (100 ng/mL) and gene expression levels of CRH-BP mRNA were measured by RT-qPCR 1, 2, and 3 days after the BDNF treatment. ***p < 0.001, Student's t-test, n = 3 independent culture dishes. (d) The amount of CRH-BP protein in cortical cultures 3 days after the BDNF treatment (0, 10, 100 ng/mL) assessed by western blot analysis. *p < 0.05, Tukey's post hoc test, n = 4 independent culture dishes.
the CRH-BP up-regulation induced by BDNF. We first tested whether histone acetyltransferases (HATs), which regulate the transcriptional activation via histone acetylation, are involved in the BDNF-induced up-regulation of CRH-BP mRNA by RT-qPCR using C646, a p300 HAT inhibitor (Fig. 4) . We observed that BDNF-induced up-regulation of CRH-BP mRNA (BDNF-treated: 11.25 AE 1.66, Control: 1.00 AE 0.04; p < 0.05) was not attenuated (two-way ANOVA, interaction effect: F 1,8 = 0.012, p > 0.05) in the presence of C646 (BDNF-and C646-treated: 10.9 AE 0.31, C646-treated: 0.80 AE 0.02; p < 0.05), indicating that the BDNF-induced up-regulation of CRH-BP is a HAT-independent event.
Histone H3K27 is expected to be highly methylated in the CRH-BP genomic region (Chr13, 96, 197, 150 ; assessed by the UCSC Genome Browser). Histone demethylases enhance the transcriptional activation via histone acetylation. KDM6A and B (also termed as UTX and JMJD3, respectively), H3K27me2/3 demethylases, regulate evaluated by western blot analysis in cortical cultures 3 days after BDNF treatment (0, 100 ng/mL in the presence or absence of K252a. N.S.: not significant, *p < 0.05, Tukey's post hoc test, n = 3 independent culture dishes. Fig. 3 Potential involvement of MEK and PI3K, but not of PLCc, in brain-derived neurotrophic factor (BDNF)-induced CRH-BP gene expression in cortical cultures. Cortical cultures were treated with 100 ng/mL BDNF in the presence or absence of inhibitors of (a) PI3K (LY293002, 10 lM), MEK (U0126, 10 lM), or (b) PLCc (U73122, 5 lM) for 3 days, and expression levels of CRH-BP mRNA were measured by real-time quantitative polymerase chain reaction (RTqPCR). *p < 0.05, **p < 0.01, ***p < 0.001, Tukey's post hoc test, n = 3 (LY293002 and U0126) or n = 4 (U73122) independent culture dishes.
histone demethylation of H3K27 (Swigut and Wysocka 2007) , and a previous transcriptome analysis demonstrated that KDM6B is up-regulated 2 h after the BDNF treatment in mouse cortical neurons (Sullivan et al. 2015) . Consistent with this, we confirmed that the amount of KDM6B mRNA was also up-regulated 1 h after BDNF treatment in our culture system. On the other hand, there were no significant changes in the amount of KDM6A mRNA. Therefore, we hypothesized that the demethylation of H3K27 by KDM6B may lead to the up-regulation of CRH-BP mRNA. We assessed immediate changes in CRH-BP, KDM6A, and KDM6B mRNA levels after BDNF treatment by RT-qPCR (Fig. 5a ). CRH-BP mRNA levels began to increase significantly 4 h after BDNF treatment (1 h: 1.10 AE 0.06, p > 0.05; 4 h: 2.43 AE 0.14, p < 0.001; 8 h: 2.48 AE 0.20, p < 0.001) compared to 0-h baseline (1.00 AE 0.64). A significant increase in KDM6A mRNA levels was detected 8 h after BDNF treatment (1 h: 1.02 AE 0.06, p > 0.05; 4 h: 1.14 AE 0.06, p > 0.05; 8 h: 1.38 AE 0.05, p < 0.05) compared to 0-h baseline (1.00 AE 0.08). On the other hand, 1 h after BDNF treatment, KDM6B mRNA levels showed a significant increase (1 h: 1.86 AE 0.14, p < 0.01; 4 h: 1.27 AE 0.11, p < 0.05; 8 h: 1.08 AE 0.11, p > 0.05) compared to 0-h baseline (1.00 AE 0.13). Thus, KDM6B, but not KDM6A, displayed a significant increase in mRNA level prior to the elevation of CRH-BP mRNA levels. We further evaluated this hypothesis using glycogen synthase kinase (GSK)-J4, a H3K27 demethylase inhibitor. BDNF-induced up-regulation of CRH-BP mRNA (BDNF-treated: 8.55 AE 0.30; Control: 1.00 AE 0.08; p < 0.001) was partially, but significantly, blocked (two-way ANOVA, interaction effect: F 1,12 = 82.82, p < 0.001) in the presence of GSK-J4 (BDNF-and GSK-J4-treated, 4.56 AE 0.23; GSK-J4-treated, 0.61 AE 0.07; p < 0.05; Fig. 5b ). Next, we assessed the signaling pathways involved in the BDNF-induced upregulation of KDM6B mRNA. Cortical cultures were stimulated with 100 ng/mL BDNF in the presence or absence of 10 lM LY293002 or 10 lM U0126, and mRNA levels of KDM6B were measured 1 h after the BDNF treatment. BDNF induced up-regulation of KDM6B mRNA (BDNF: 2.03 AE 0.22, p < 0.001 compared to Control: 1.00 AE 0.08), and the up-regulation was significantly attenuated in the presence of U0126 (1.37 AE 0.09, p > 0.05 compared to Control), but not in the presence of LY293002 (1.77 AE 0.13, p < 0.01 compared to Control) (Fig. 5c ). These observations suggest that BDNF is able to induce the up-regulation of KDM6B mRNA via MEK, but not via PI3K.
Intracellular distribution and activity-dependent secretion of CRH-BP in cortical neurons
To assess the intracellular distribution of CRH-BP, we generated pH-sensitive mutants of green fluorescent protein (pHluorin)-fused construct of CRH-BP (CRH-BP-pHluorin). We performed fluorescent microscopy on cultured cortical neurons transduced with CRH-BP-pHluorin-and BDNFmCherry-expressing vectors (Fig. 6a) . The pHluorin fluorescent signals were detected in a granule-like pattern and there was a certain population of pHluorin fluorescent signals colocalized with those of mCherry in cortical neurons. This suggested that CRH-BP was stored in BDNF-containing granules. In addition, fluorescence imaging revealed that the pHluorin signals did not merge with those of the immune signals of LAMP2, which is a marker for lysosomes, suggesting that the CRH-BP-pHluorin protein was not transported into lysosomes (Fig. 6b) . These observations suggested that CRH-BP in cortical neurons was stored into regulatory secretory vesicles containing BDNF.
Subsequently, to evaluate whether CRH-BP is secreted in an activity-dependent manner, we performed live-cell imaging on cultured cortical neurons transduced with CRH-BPpHluorin-expressing vectors. Twenty-four hours after the gene transduction, the neurons were stimulated with 50 mM potassium (high K). Drastic changes (acute increase and gradual decrease) in pHluorin fluorescence were detected in the neurites of cortical neurons upon high K treatment ( Fig. 7 ; movie file is available as Data S1), indicating that CRH-BP is secreted in an activity-dependent manner from the cortical neurons.
Assessment of the impact of neuronal activity on the BDNFinduced up-regulation of CRH-BP gene expression of in cortical neurons Finally, we verified whether neuronal activity was involved in the up-regulation of CRH-BP gene expression induced by BDNF. Cortical cultures stimulated with 100 ng/mL BDNF Fig. 4 Brain-derived neurotrophic factor (BDNF)-induced up-regulation of CRH-BP was not inhibited by C646, a histone acetyltransferase type B catalytic subunit 1 (HAT1) inhibitor, in cortical cultures. Primary cultures of rat cerebral cortical neurons were treated with or without BDNF (100 ng/mL) for 3 days in the presence or absence of 10 lM C646 and expression levels of CRH-BP mRNA were measured by real-time quantitative polymerase chain reaction (RT-qPCR). ***p < 0.001, Tukey's post hoc test, n = 4 independent culture dishes.
were incubated for 3 days (DIV6-9) in the presence or absence of 1 lg/mL of tetrodotoxin (TTX), a selective sodium channel blocker, and the amounts of CRH-BP mRNA were measured by qPCR (Fig. 8a) . The BDNFinduced up-regulation of CRH-BP mRNA (BDNF-treated: 19.8 AE 0.44, Control: 1.00 AE 0.04; p < 0.01) was partially, but significantly, attenuated (two-way ANOVA, interaction effect: F 1,8 = 181.5, p < 0.001) in the presence of TTX (BDNF-and TTX-treated: 11.11 AE 0.43, TTX-treated: 0.59 AE 0.01; p < 0.05). On the other hand, western blot analysis revealed that the BDNF-induced up-regulation of CRH-BP protein (BDNF-treated: 2.04 AE 0.03, Control: 1.00 AE 0.04; p < 0.05) was not significantly inhibited (two-way ANOVA, interaction effect: F 1,8 = 0.672, p < 0.05) by TTX treatment (BDNF-and TTX-treated: 1.73 AE 0.02, TTX-treated: 0.85 AE 0.10; p < 0.05; Fig. 8b ). These observations indicate that BDNF can up-regulate CRH-BP expression in a neuronal activity-independent manner in cortical neurons.
Discussion
In this study, we investigated (i) the regulatory role of BDNF in gene expression of CRH-BP and its molecular basis and (ii) the subcellular localization and secretion of CRH-BP in primary cultures of rat cerebral cortical neurons, and discovered the following (summarized in Fig. 9 ): First, BDNF up-regulated the gene expression of CRH-BP through the activation of signaling molecules, including TrkB, MEK, and KDM6B, and is able to lead to the CRH-BP upregulation in a neuronal activity-independent manner. Second, CRH-BP was stored into BDNF-containing granules in cortical neurons, from which it was secreted in an activitydependent manner. , and 8 h after treatment with 100 ng/mL BDNF, the amounts of CRH-BP, KDM6A, and KDM6B mRNA were quantified in primary cerebral cortical cultures. *p < 0.05, **p < 0.01, ***p < 0.001, Tukey's post hoc test, n = 3 independent culture dishes. (b) Primary cultures of rat cerebral cortical neurons were treated with or without BDNF (100 ng/mL) for 3 days in the presence or absence of 30 lM GSK-J4 and expression levels of CRH-BP mRNA were measured by RT-qPCR. ***p < 0.001, Tukey's post hoc test, n = 4 independent culture dishes. (c) Cortical cultures were stimulated with 100 ng/mL BDNF in the presence or absence of 10 lM LY293002 or 10 lM U0126, and mRNA levels of KDM6B were measured 1 h after the BDNF treatment by RTqPCR. N.S.: not significant, **p < 0.01, ***p < 0.001, Tukey's post hoc test, n = 4 independent culture dishes.
Our in vitro assay identified signal molecules that were involved in the BDNF-up-regulating CRH-BP gene expression, namely TrkB, MEK, presumably ERK and KDM6B. On the other hand, inhibitors for PLCc and p300 HAT failed to attenuate significantly the BDNF-induced up-regulation of CRH-BP mRNA. It is therefore likely that the PLCccalcium-Cyclic adenosine monophosphate response elementbinding protein (CREB)/p300 pathway is not responsible for the BDNF-induced CRH-BP up-regulation. TTX partially inhibited the BDNF-induced up-regulation of CRH-BP mRNA, while no significant effects were detected in CRH-BP protein levels, indicating that BDNF is able to upregulate CRH-BP gene expression in a neuronal activityindependent manner. It is plausible that the CRH-BP promoter(s) that are responsible for its constitutive expression are involved in the BDNF-induced CRH-BP gene expression. BDNF markedly up-regulated not only CRH-BP gene expression, but also that of CRH. On the other hand, the transcriptomic impacts of BDNF on CRHRs were not robust.
Indeed, BDNF was able to up-regulate CRHR1 mRNA significantly, but slightly, and there were no significant changes in the expression level of CRHR2 mRNA. Jørgensen et al. (2013) reported a robust, approximately 4.0-fold increase in mRNA levels in CRHR1 4-h following BDNF treatment that lasted for a few hours. On the other hand, in this study, an increase in CRHR1 mRNA levels were only detected 3 days after BDNF treatment. This discrepancy may have been caused by differences in the maturity of cortical cells in our respective cultures. In particular, the cultured cortical neurons Jørgensen et al. used were less mature (cultured at E18; assayed at DIV 5-7), compared to the cultured neurons in this study (cultured at E20; assayed at DIV 9-10). Therefore, in this study, signaling molecules/pathway involved in CRH and CRHR1 gene expression remained unaddressed. This is, to the best of our knowledge, the first study assessing the intracellular distribution of CRH-BP in cortical neurons. Although the type of cell (e.g., glutamatergic neurons, GABAergic neurons) in which CRH-BP is upregulated by BDNF remains unclear, CRH-BP-pHluorin was distributed in the vesicular pattern and co-localized with BDNF, which is known to be stored in secretory vesicles (Goodman et al. 1996; Mowla et al. 1999) . Taken together, these observations indicated that CRH-BP is sorted into secretory granules, from which CRH-BP is secreted in an activity-dependent manner. This is consistent with a previous study in PC12 cells, in which CRH-BP was reported to be co-localized with SecII-positive granules and was secreted upon high-K stimulation (Blanco et al. 2011) . It is suggested that CRH-BP is secreted together with BDNF, but it remains unexplained whether there is any physiological significance for the simultaneous secretion of BDNF and CRH-BP in cortical neurons.
In infantile spasms, it is proposed that the CRH protein plays a role in epileptogenesis (Galanopoulou 2013) . In addition, a recent study reported that the CRH and CRHR1 expression levels were significantly up-regulated in brains of patients with infantile spasms (Yang et al. 2017) . In a rat protein assessed in cortical cultures 3 days after treatment with or without BDNF (100 ng/mL) in the presence or absence of TTX by western blot analysis. *p < 0.05, Tukey's post hoc test, n = 3 independent culture dishes. model of epilepsy, the mRNA levels of CRH-BP and BDNF were both significantly up-regulated. In particular, the CRH-BP mRNA level was increased in the hippocampal CA1 region upon the induction of epilepsy, and BDNF and CRH-BP mRNAs were up-regulated in the hippocampal dentate gyrus (GSE1994) (Borges et al. 2007 ). Our present results indicated that the BDNF-induced up-regulation of CRH-BP is a neuronal activity-independent event. Therefore, it is possible that the up-regulation of the CRH-BP gene in epilepsy is not directly led by neuronal hyperexcitability in epilepsy, but by BDNF, which is known to be up-regulated upon epilepsy (Mud o et al. 1996) . The up-regulated CRH-BP can form a complex with CRH whose expression level is also increased. The complex formation can subsequently reduce the amount of free-CRH, which may contribute to the termination of seizures induced by CRH. It is of interest to assess whether the up-regulation of CRH-BP is induced by the up-regulated BDNF, and whether the up-regulated CRH-BP plays any pathogenic roles in epilepsy by regulating CRH bioactivity. The BDNF-induced CRH-BP expression may represent a novel therapeutic target for epilepsy.
Further biochemical and physiological analyses are still required to elucidate the precise molecular mechanism and biological significance of the BDNF-induced up-regulation of CRH-BP in the CTX, through which CRH-BP may negatively regulate the CRH signal transduction. It is also of interest to address the type of cell in which the BDNFinduced up-regulation of CRH-BP takes place and whether there is any functional significance for co-localization of BDNF and CRH-BP in cortical secretory granules. We expect that the CRH-BP-pHluorin construct, which we generated for this study, is useful for further revealing the intracellular dynamics of CRH-BP not only in cortical neurons, but also in various cell types.
Supporting information
Additional Supporting Information may be found online in the supporting information tab for this article: Figure S1 . Cortical cultures were pretreated with or without 10 lM LY293002 (LY; a PI3K inhibitor) and 10 lM U0126 (a MEK inhibitor) for 20 min, and phosphorylation levels of Akt and ERK1/ 2 were evaluated 5 min after the BDNF treatment by western blot analysis.
Data S1. Live-cell imaging of activity-dependent secretion of CRH-BP-pHluorin from cortical neurons. 
